3 Reasons Royalty Pharma Is a Dividend Stock You Never Have to Sell

Pharmaceutical companies search for and develop drugs that they hope will one day generate large profits. However, the drug ...
Yahoo Finance

Royalty Pharma Reports Q4 and Full Year 2025 Results

Portfolio Receipts of $874 million in Q4 2025 and $3,254 million for FY 2025 Portfolio Receipts growth of 18% in Q4 2025 and 16% for FY 2025Net cash provided by operating activities of $827 million in ...
Forbes

The Top 10 Gold Royalty And Streaming Companies

This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. Gold colored crown on black background. Horizontal composition. Gold has endured for ...
Seeking Alpha

Royalty Pharma to pay up to $425M for royalty interest in AstraZeneca’s cliramitug

Royalty Pharma (RPRX) on Wednesday announced plans to spend up to $425M to acquire a portion of royalty interest in cliramitug, a heart disease therapy developed by AstraZeneca (AZN) and Neurimmune.
Investopedia

Understanding the 25% Rule: Government Debt and Royalty Guidelines

Investopedia contributors come from a range of backgrounds, and over 25 years there have been thousands of expert writers and editors who have contributed. Vikki Velasquez is a researcher and writer ...